BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, December 22, 2025
See today's BioWorld
Home
» China's GIBH working with Euclises on COX-2 inhibitor portfolio
To read the full story,
subscribe
or
sign in
.
China's GIBH working with Euclises on COX-2 inhibitor portfolio
Dec. 8, 2014
By
Cornelia Zou
HONG KONG – China's government-founded Guangzhou Institutes of Biomedicine and Health (GIBH) has partnered with a U.S. biotech company to co-develop its cancer candidate.
BioWorld
